Long-term registry following people with psoriasis on systemic treatments
Follows adults with psoriasis over 10 years on systemic treatments, including biologics.
Key facts
- Who runs it
- Swiss Dermatology Network for Targeted Therapies
- Where
- Aarau, Basel, Bern, Lausanne, Sankt Gallen, and Zurich, SwitzerlandSee the 6 sites
- Trial code
- Registry title
- Swiss Dermatology Network of Targeted Therapies (SDNTT)
- Status
- Recruiting
- People taking part
- 1,121 people, planned
- Started
- Feb 2011
- Expected to end
- 15 Mar 2032
- Type of study
- Observational, 8 groups
- Treatments tested
- Adalimumab
- Etanercept
- Infliximab
- Ustekinumab
- Cyclosporine A
- Fumaric acids
- Methotrexate
- Other anti-psoriatic systemic treatments
- Record updated
- 29 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with plaque-type psoriasis or psoriatic arthritis who are starting a biologic or conventional systemic drug for the first time. They stay in the registry for 10 years.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Plaque-type psoriasis or psoriatic arthritis, confirmed by a dermatologist
- Earlier treatment
- Must be getting a specific biologic or conventional systemic drug for the first time
Main reasons for not taking part
- No informed consent
- Taking part in another clinical trial on the day of registration (data are analysed separately)
- Not enough language skills in German, French, Italian or English to give consent
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a dermatologist,
- age ≥ 18,
- Being administered a specific biologic/conventional systemic drug for the first time
- Sufficient language skills (German, French, Italian and English) for the informed consent to participate
- Informed consent to participate
Who cannot take part
- Lack of informed consent
- Patients being participants of clinical trials at the day of registration to the registry (if a patient is included into a clinical trial during the registry follow-ups, the patient data will be recorded, but analyzed separately)
Where in Switzerland
- Aarau Cantonal HospitalAarau, SwitzerlandContact: Marcus Streit, Dr. med.Taking people
- Basel University HospitalBasel, SwitzerlandContact: Alexander Navarini, Prof.Taking people
- Inselspital, Bern University HospitalBern, SwitzerlandContact: Luca Borradori, Prof.Taking people
- Centre Hospitalier Universitaire Vaudois (CHUV)Lausanne, SwitzerlandContact: Michel Gilliet, Prof.Taking people
- St. Gallen Cantonal HospitalSankt Gallen, SwitzerlandContact: Antonio Cozzio, Prof.Taking people
- Zurich University HospitalZurich, SwitzerlandContact: Tatjana Maul, PD Dr.Taking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the long-term course of patients with psoriasis and psoriatic-arthritis in systemic treatments such as, methotrexate, cyclosporin A, fumaric acids, acitretin, systemic PUVA, etanercept, infliximab, adalimumab and ustekinumab. A patient will be included at first initiation of the treatment and will remain in the registry for 10 years, regardless of subsequent therapy.
Read full original descriptionShow less
The registry will also evaluate safety clinical outcomes and health related quality of life.
The 8 groups in the trial
- Adalimumab
Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed
- Etanercept
Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed
- Infliximab
Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed
- Ustekinumab
Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed
- Cyclosporine A
Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed
- Fumaric acids
Intervention: Drug: conventional systemic: Fumaric acids, all dosages, frequencies and durations prescribed
- Methotrexate
Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed
- Other anti-psoriatic systemic treatments
e.g.: Intervention: Drug: conventional systemic: Acitretin or Systemic phototherapy (PUVA), all dosages, frequencies and durations prescribed
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Long-Term Benefits and Safety of Systemic Psoriasis Therapy: Swiss Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics
- Plain-language title
- Long-term registry following people with psoriasis on systemic treatmentsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 29 November 2024